Mark Mapstone

picture of Mark  Mapstone

Professor of Clinical Neurology
School of Medicine

Chief, Neuropsychology Section
School of Medicine

Faculty, Institute for Memory Impairments and Neurological Disorders (UCI MIND)

Fellow, Center for the Neurobiology of Learning and Memory


Ph.D., Northwestern University, 2000, Clinical Psychology

Phone: (949) 824-7184
Email: mark.mapstone@uci.edu

University of California, Irvine
318 Sprague Hall
839 Health Sciences Road
Mail Code: 3910
Irvine, CA 92697
Research Interests
Cognitive Phenotyping, Biomarkers of Neurological Disease, Cognitive Neuroscience
Academic Distinctions
1996, University Scholar, The Graduate School, Northwestern University
1998, Fellow, Buehler Center on Aging, Northwestern University Medical School
2000, George Yacorzinski Scholar, Northwestern University Medical School
2001, NIH Post-doctoral Fellowship, University of Rochester
2003, NIH Career Development Award (K23)
2004, John Henry Hobart Fellow in Ethics and Social Justice, Hobart College
Appointments
2000-2002, Post-doctoral Fellow, Clinical Neuropsychology, University of Rochester School of Medicine
2002-2008, Assistant Professor, Neurology, University of Rochester School of Medicine
2008-2015, Associate Professor, Neurology, University of Rochester School of Medicine
2015- present, Adjunct Professor, Neurology, University of Rochester School of Medicine
Research Abstract
I am a translational neuroscientist. My goal is to translate discoveries about the aging brain into practical and implementable approaches for successful cognitive aging at the individual level. My current work is focused on early detection of age-related neurological disease especially Alzheimer’s disease and Parkinson’s disease using careful cognitive phenotyping and biomarkers obtained from blood. We are using this information to develop screening tools that can be used to enrich clinical trials with appropriate subjects for disease modifying interventions. We hope to develop reliable biomarkers for clinical use.
Publications
Publications from the past 3 years (2017-2020)

Lin F, Ren P, Mapstone M, Meyers S, Porsteinsson A, Baran T. (2017). The cingulate cortex of older adults with excellent memory capacity. Cortex 86, 83-92. DOI: 10.1016/j.cortex.2016.11.009

Mapstone M, Lin F, Nalls MA, Cheema AK, Singleton AB, Fiandaca MS, Federoff HJ. (2017). What Success Can Teach Us About Failure: The Plasma Metabolome of Older Adults with Superior Memory and Lessons for Alzheimer's Disease. Neurobiology of Aging. 51, 148-155. PMID: 27939698.

Mapstone M. Cheema AK, Zhong X, Fiandaca MS, Federoff HJ. (2017). Biomarker Validation: Methods and Matrix Matter. Alzheimer’s and Dementia. 13(5), 608–609. 10.1016/j.jalz.2016.11.004.

Grill, J, Apostolova L, Bullain S, Burns J, Cox C, Dick M, Hartley D, Kawas C, Kremen S, Lingler J, Lopez O, Mapstone M, Pierce A, Rabinovici G, Roberts JS, Sajjadi SA, Teng E, Karlawish J. (2017). Communicating Mild Cognitive Impairment diagnoses with and without amyloid imaging. Alzheimer’s Research and Therapy, 9:35 DOI 10.1186/s13195-017-0261-y.

Chapman BP, Benedict RHB, Lin F, Roy S, Federoff HJ, Mapstone M. (2017). Personality and performance in specific cognitive domains among older persons. American Journal of Geriatric Psychiatry. 25(8): 900-908. DOI: 10.1016/j.jagp.2017.03.006.

Chapman BP, Benedict RHB, Lin F, Roy S, Szigeti K, Federoff HJ, Mapstone M. (2017). Apolipoprotein E genotype impact on memory and attention in older persons: The moderating role of personality phenotype. International Journal of Geriatric Psychiatry. Jun 14. DOI 10.1002/gps.4748.

Zhuang Y, Qiu X, Wang L, Qing MA, Mapstone M, Luque A, Weber MT, Tivarus M, Miller E, Arduino RC, Zhong J, and Schifitto G. (2017). Combination anti-retroviral therapy improves cognition and functional connectivity in treatment naïve HIV-infected individuals. Journal of Neurovirology. 23(5): 704–712. DOI 10.1007/s13365-017-0553-9.

Mehta K, Wu H-J, Menon S, Fallah Y, Zhong X, Rizk N, Unger K, Mapstone M, Fiandaca MS, Federoff HJ, and Cheema AK. (2017). Metabolomic biomarkers of pancreatic cancer - a meta-analysis study. Oncotarget. Sep 15; 8(40): 68899–68915. DOI: 10.18632/oncotarget.20324

Wang XX, Ren P, Mapstone M, Conwell Y, Porsteinsson A, Foxe J, Raizada R, Lin F, for the Alzheimer’s Disease Neuroimaging Initiative. (2017). Identifying a shared neural circuit linking multiple neuropsychiatric symptoms with Alzheimer’s Pathology. Brain Imaging and Behavior. Sep 15. DOI: 10.1007/s11682-017-9767-y.

Wang XX, Ren P, Baran T, Raizada R, Mapstone M, Lin F. (2017). Longitudinal functional brain mapping in Supernormals. Cerebral Cortex. Nov 23:1-11. DOI: 10.1093/cercor/bhx322.

Fiandaca MS, Mapstone M, Connors E, Jacobson M, Monuki E, Malik S, Macciardi F, and Federoff HJ. (2017). Systems Healthcare: A Holistic Paradigm for Tomorrow. BMC Systems Biology. 11: 142. PMID: 29258513.

Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S.(2018). Precision pharmacology for Alzheimer's disease. Pharmacological Research. PMID: 29458203

Fiandaca MS, Mapstone M, Mahmoodi A, Gross TJ, Macciardi F, Cheema A, Merchant-Borna K, Bazarian J, Federoff HJ. (2018). Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls. PLoS ONE 13(4): e0195318. PMID: 29677216.

Zimmerman J, Perry A, Breakspear M, Schirner M, Sachdev P, Wen W, Kochan N, Mapstone M, Ritter P, McIntosh AR, Solodkin A. (2018). Differentiation of Alzheimer’s disease based on local and global parameters in personalized Virtual Brain models. NeuroImage: Clinical 19:240-251. DOI: 10.1016/j.nicl.2018.04.017.

Gross T, Mapstone M, Miramontes R, Padilla R, Cheema AK, Macciardi F, Federoff HJ, Fiandaca MS (2018). Toward reproducible results from targeted metabolomic studies: Perspectives for data pre-processing and a basis for analytic pipeline development. Current topics in Medicinal Chemistry. DOI: 10.2174/1568026618666180711144323.

Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca MS, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S. (2018). Precision pharmacology for Alzheimer’s disease. Pharmacological Research,130:331-365. https://doi.org/10.1016/j.phrs.2018.02.014.

Fiandaca MS, Gross TJ, Johnson TM, Hu MT, Evetts S, Wade-Martins R, Merchant-Borna K, Bazarian J, Cheema AK, Mapstone M, and Federoff HJ. (2018). Potential Metabolomic Linkage in Blood Between Parkinson’s Disease and Traumatic Brain Injury. Metabolites. 8(3): 50. PMID: 30205491.

Chapman RM, Gardner MR, Klorman R, Mapstone M, Porsteinsson AP, Antonsdottir IM, Kanalyan L. (2018) Temporospatial component of brain ERP’s as biomarkers for Alzheimer’s disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 10, 604-614.

Hampel H, Vergallo A, Afshar M, Akman-Anderson L, Benda N, Batrla R, Broich K, Caraci F, Cuello AC, Emanuele E, Haberkamp M, Kiddle SJ, Mapstone M, Verdooner SR, Woodcock J, Lista S. (2019). Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease. Dialogues in Clinical Neuroscience. 21(2):177-191. PMID: 31636492

Gross TJ, Doran E, Cheema AK, Head E, Lott IT, and Mapstone M. (2019). Plasma metabolites related to cellular energy metabolism are altered in adults with Down syndrome and Alzheimer’s disease. Developmental Neurobiology, 79(7):622-638. DOI: 10.1002/dneu.22716.

Mapstone M, Gross TJ, Macciardi F, Cheema AK, Head E, Handed BL, Klunk WE, Christian BT, Silverman W, Lott IT, Schupf N for the ABC-DS (2020).Metabolic correlates of prevalent mild cognitive impairment and Alzheimer’s disease in adults with Down Syndrome. Alzheimer’s & Dementia: Diagnosis and Disease Monitoring.

Handen BL, Lott IT, Christian BT, Schupf N, O’Bryant S, Mapstone M, Fagan AM, Lee J, Tudorascu D, Wang MC, Head E, Klunk W, Ances B, Lai F, Zaman S, Krinsky-McHale S, Brickman AM, Rosas HD, Cohen A, Andrews H, Hartley S, Silverman W, and for the Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS). (2020). The Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS): Rationale and Methodology. Alzheimer’s & Dementia: Diagnosis and Disease Monitoring.

Petersen ME, Zhang F, Schupf N, Krinsky-McHale SJ, Hall J, Mapstone M, Cheema A, Silverman W, Lott IT, Rafii MS, Handen BL, Klunk WE, Head E, Christian BT, Foroud T, Lai F, Rosas DH, Zaman S, Ances B, Wang M-C, Tycko B, Lee JH, and O’Bryant S, (2020). Proteomic Profiles for Alzheimer’s Disease and Mild Cognitive Impairment Among Adults with Down Syndrome Spanning Serum and Plasma: An ABC-DS Study. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.

Rafii MS, Petersen ME, Julovich D, Zhang F, Hall J, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Foroud T, Lai F, Rosas DH Zaman S, Wang M-C, Tycko B, Lee J, Handen B, Fortea J, and O’Bryant S, for the Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS). (2020). Plasma tau and Neurofilament light (NfL) as diagnostic biomarkers of Alzheimer’s Disease in adults with Down syndrome. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.

Rafii MS, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Foroud T, Lai F, Rosas DH Zaman S, Petersen ME, Strydom A, Fortea J, Handen B, and O’Bryant S, Ph.D. (2020). The A/T/N Framework for Alzheimer's Disease in Adults with Down Syndrome. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.
Grant
R01 AG058644-01 (Mapstone, PI) Multi-omic Investigation of Exercise Effects in MCI
Professional Societies
Society for Neuroscience
International Neuropsychology Society
International Society for Behavioral Neuroscience
American Academy of Neurology
Graduate Programs
Interdepartmental Neuroscience Program

Neurology

Research Center
Translational Laboratory and Biorepository (TLaB)
Last updated
07/10/2020